pirtobrutinib

{
  "id": "MLC-T-ONC-006699",
  "term": "pirtobrutinib",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used to treat adults with chronic lymphocytic leukemia, small lymphocytic lymphoma, or mantle cell lymphoma that was treated with at least two other types of therapy, including a BTK inhibitor. It is also being studied in the treatment of other types of cancer. Pirtobrutinib blocks a protein called BTK, which may help keep cancer cells from growing. It is a type of tyrosine kinase inhibitor. Also called Jaypirca.",
    "An orally available, selective, non-covalent Bruton's tyrosine kinase (BTK) inhibitor with potential antineoplastic activity. Upon oral administration, pirtobrutinib selectively and reversibly binds to BTK. This prevents both the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways, thereby inhibiting the growth of malignant B-cells that overexpress BTK. Reversible binding of LOXO-305 may preserve antitumor activity in the presence of certain acquired resistance mutations, including C481 mutated BTK, and limit toxicity associated with inhibition of other non-BTK kinases. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed or mutated in B-cell malignancies; it plays an important role in the development, activation, signaling, proliferation and survival of B lymphocytes."
  ],
  "synonyms": [
    "Jaypirca",
    "BTK inhibitor LOXO-305"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/pirtobrutinib/"
}